HCV Protease Inhibitor Telaprevir Improves Response, Halves Treatment Time For Hepatitis C Patients
Boceprevir eliminated Hep C virus in unprecedented number of patients
New medicine works on hepatitis C
Deaths Due to Hepatitis C Have Increased Dramatically over the Past Decade
Cannabis use in patients with Hep C is associated with fibrosis
Endelig fri og frisk
Loan $25 to change lives through Kiva.org
Loan $25 to change lives through Kiva.org
Iron has a carcinogenic role in chronic liver disease
Hep C genotype 1b is a risk factor for hepatocellular carcinoma
the World Hepatitis Awareness Day (WHAD) 2007 Media Event
Hepatitis Vaccine Showing Progress
Five Million Infected With Hepatitis C in Egypt
Five Million Infected With Hepatitis C in Egypt
Heavy drinking means early death for women with hepatitis C
Heavy drinking means early death for women with hepatitis C
Schering-Plough, Orasure to develop hepatitis C test
China's Hepatitis C Prevalent Population is Ten Times that of the United States
Roche initiates phase II study for hepatitis C therapy
World Health Organization Urges Europe-Wide Hepatitis Plan
Hepatitis C from tainted blood products
Alcohol users with hepatitis often untreated
Milk Thistle for Alcoholic and/or Hepatitis B or C Liver Diseases:
Mother-to-Child Hepatitis C Transmission Twice As Likely Among Infant Girls As Boys, Study Says
Mother to child transmission of hepatitis C virus, breastfeeding does not increase risk
European Governments Warned: Take Action on Hepatitis C Now or Risk a Global Epidemic
Smoking and hepatitis C up risk of lymphoma
European consensus meeting draws up guidelines on HIV and hepatitis
Majority of Treatment Nonresponders in UK Study Do Not Wish to Discontinue Treatment
Liver Cancer Fastest Growing Cancer in USA
Liver Cancer Fastest Growing Cancer in USA
Researchers how some patients self-recover from hepatitis C
Hepatitis Vaccination in Patients With Chronic Liver Disease
A New Tool Can Estimate the Probability of Whether an Individual Patient Will Achieve an SVR After Combination Treatment with Pegasys/Copegus
Survival of Cirrhotic Patients with Hepatocellular Carcinoma
Light and Moderate Alcohol Intake May Have Minimal or No Effect on Fibrosis Development in HCV Infection
Hepatitis C a Direct Cause of Diabetes
Weight Loss and Exercise Improve Liver Disease
Extrahepatic Manifestations of Hepatitis C Among United States Male Veterans
Doctors warn of death toll from 'silent epidemic' of hepatitis C
In Patients on Interferon/Ribavirin Therapy, HCV Viral Kinetics Within the First 24 Hours Is a Useful Predictor of Treatment Response
Hepatitis victim awarded $551,600 over tattooed lip coloring
Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey
Study shows 24 weeks of PegIntron combination therapy as effective as 48 weeks in genotype 2/3 hepatitis C patients
Pilot study of the relationship between histologic progression and hepatic
DEPRESSIVE SYMPTOMS DURING IFN-ALPHA/RIBAVIRIN THERAPY ARE ASSOCIATED WITH REDUCED VIRAL CLEARANCE IN PATIENTS WITH HEPATITIS C
Chronic hepatitis C: updated Swedish consensus.
Schering-Plough to Initiate First Head-to-Head Study of PEG-Intron Versus Pegasys for Chronic HCV Infection
"Hepatitis respects no borders".
FDA Grants Marketing Approval to Schering-Plough's Rebetol for Treatment of Hepatitis C in Children
24 Weeks of Therapy with Peginterferon Alfa Plus Ribavirin Is Sufficient for HCV Genotypes 2 and 3
Does Prior Hepatitis A Virus (HAV) Infection Affect the Progression of Chronic Hepatitis C?
New Pegasys Trial to Enroll Hepatitis C Patients Not Helped by PEG-Intron
Early Responders to PEG-Intron (peginterferon alfa-2b) Plus Ribavirin Have a Significant Reduction in HCV RNA at 48 hours That May Be Pivotal in Achieving a Sustained Viral Response
Diagnosis of Acute Hepatitis C: Test for Anti-HCV or HCV-RNA?
HCV Quasi-species Dynamics During Pegasys (peginterferon alfa-2a) and Ribavirin Combination Therapy
Treatment of Recurrent Hepatitis C After Liver Transplantation with PEG-Intron (peginterferon alfa-2b) Plus Ribavirin: A Preliminary Analysis
Interaction of Steatosis and Non-Alcoholic Steatohepatitis (NASH) in Chronic Hepatitis C
Hepatitis C Drug Market to Grow from $2.5 Billion in 2002 to More Than $9 Billion in 2012
Key to hepatitis virus persistence found
FDA Grants Priority Review to New Formulation of Rebetol (ribavirin) for Treatment of Children with Chronic Hepatitis C
HCV RNA in the Semen of Patients with Chronic HCV Infection
Artificial human liver created
HCV Infection Identified as Risk Factor for Other Infections
Improved Hepatitis C Survival
Steatosis Accelerates Liver Damage in HCV Patients
Study: Depression More Likely to Strike Women Receiving Interferon for Hepatitis
Patients with Psychiatric Disorders Can Tolerate Interferon with Appropriate Support
Russian delegation visits University Hospitals in Copenhagen
Porphyria cutanea tarda
High Response Rates Seen in Previous Interferon/Ribavirin Non Responders
The Second Phase HCV Decline Slope Is the Best Predictor of Sustained Viral Response During Treatment of Chronic HCV Genotype 1
Roche dramatically reduces cost of combination therapy
Prevalence of hepatitis C among psychiatric patients in the public sector.
Stunning Glimpse Into The Future of HCV Therapy
Rising HCV Rates and Sexual Transmission
Autoimmune disorder more common in chronic hepatitis C than suspected
Autoimmune disorder more common in chronic hepatitis C than suspected
RETREATMENT OF HCV NON-RESPONDERS WITH PEGINTERFERON AND RIBAVIRIN
THE DISCOVERY OF BILN 2061 - AN ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITOR
Risk factors for hepatocellular carcinoma
Maternal-infant transmission of hepatitis C virus infection.
Children with hepatitis C.
Communities Protest Pricing of New Roche HCV Drug Pegasys
FDA approves PEGASYS (peginterferon alfa-2a) for the Treatment of hepatitis C
Reuse of Needle at Hospital Infects 50 With Hepatitis C
Organ donor infects people with liver disease hepatitis C, Oregon doctors say
Tattooing Is a Major Route of Hepatitis C Infection, Says Researcher
NIH Issues Final Version of Consensus Guidelines for the Management of Hepatitis C
Living donor liver transplantation is feasible and safe
Living donor liver transplantation is feasible and safe
Erectile Dysfuncton More Prevalent in Hepatitis C Patients
Life expectancy can be increased in chronic hepatitis C patients
Highlights of the Eighth Congress of the International Liver Transplantation Society
Pamela Anderson to be treated for hepatitis C
Fatigue occurs in more than half of patients with HCV
Hepatitis C virus (HCV) in chrildren
Pegasys wins EU approval
Stanford researcher identifies genes pointing to liver cancer
Endoscopic screening for varices in cirrhosis.
Hepatitis C - transmission by toothbrushes ?
Management of Hepatitis C: An NIH Consensus Development Conference Set for June 2002
Smoking Can Aggravate Hepatitis C Liver Damage
Some Individuals May Be Able to Develop Immunity to Hepatitis C
PEG interferon and ribavirin reduce liver fibrosis rate in hepatitis C
<< Previous
